Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last kr229.50 SEK
Change Today +1.50 / 0.66%
Volume 1.2K
As of 5:52 AM 05/4/15 All times are local (Market data is delayed by at least 15 minutes).

biogaia ab-b shs (BIOGB) Snapshot

Open
kr228.00
Previous Close
kr228.00
Day High
kr230.50
Day Low
kr226.50
52 Week High
04/27/15 - kr234.00
52 Week Low
10/13/14 - kr151.00
Market Cap
4.0B
Average Volume 10 Days
25.2K
EPS TTM
kr8.54
Shares Outstanding
16.5M
EX-Date
05/8/15
P/E TM
26.9x
Dividend
kr3.46
Dividend Yield
3.05%
Current Stock Chart for BIOGAIA AB-B SHS (BIOGB)

Related News

No related news articles were found.

biogaia ab-b shs (BIOGB) Related Businessweek News

No Related Businessweek News Found

biogaia ab-b shs (BIOGB) Details

BioGaia AB develops, markets, and sells probiotic products with documented health benefits worldwide. It operates through Paediatrics, Adult Health, and New Business segments. The company provides BioGaia ProTectis digestive health probiotic drops, as well as BioGaia ProTectis D3 drops with vitamin D3 containing lactobacillus reuteri protectis for children; and BioGaia ProTectis ORS, a probiotic oral rehydration solution with zinc. It also offers BioGaia ProTectis chewable tablet, a dietary supplement containing lactobacillus reuteri protectis, as well as BioGaia ProDentis oral lozenges, a dietary supplement containing lactobacillus reuteri prodentis for adults and children; BioGaia Gastrus, a probiotic supplement that could enhance treatment of Helicobacter pylori infection; and BioGaia ProTectis straw that provides lactobacillus reuteri protectis to various beverages. In addition, the company offers ProDentis oral health tablet for the treatment of periodontal disease and gingivitis; and component products, which are bacterial cultures of lactobacillus reuteri protectis that are used as ingredients in yoghurt and other dairy products. Further, it provides animal health products. The company sells its products through pharmacies and related outlets. BioGaia AB was founded in 1990 and is headquartered in Stockholm, Sweden.

95 Employees
Last Reported Date: 02/12/15
Founded in 1990

biogaia ab-b shs (BIOGB) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

biogaia ab-b shs (BIOGB) Key Developments

Biogaia Announces Positive Results in First Chinese Study with BioGaia's Drops in Infants with Colic

BioGaia announced positive results in first Chinese study with BioGaia's drops in infants with colic. A Chinese study of infants with colic shows that babies given Lactobacillus reuteri Protectis cry significantly less compared to babies given placebo. The newly published study is the fifth positive colic study with Lactobacillus reuteri Protectis and the results confirm the positive results of earlier studies. Treatment success was observed in all infants supplemented by Lactobacillus reuteri Protectis while it was seen in barely 16% of the placebo group. In addition, the study showed 100% parent satisfaction in the Lactobacillus reuteri Protectis group, while barely 16% among parents of children in the placebo group reported treatment satisfacion. 42 infants were included in the study.

BioGaia AB Proposes Dividend, Payable on May 15, 2015

The board of directors of BioGaia AB proposed that the shareholders be paid a dividend of SEK 5 per share, with the record date on May 11, 2015. Dividends are expected to be disbursed by Euroclear Sweden AB on May 15, 2015.

BioGaia Signs Exclusive Agreement for Oral Health Products in Mexico

BioGaia has signed an exclusive agreement with Silanes for the rights to sell BioGaia's oral health lozenges in Mexico. The launch is planned to take place during 2015.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BIOGB:SS kr229.50 SEK +1.50

BIOGB Competitors

Market data is delayed at least 15 minutes.

Company Last Change
BLIS Technologies Ltd $0.02 NZD 0.00
Danone SA €65.32 EUR +0.81
Nestle SA SFr.73.25 CHF +0.35
Novartis AG SFr.96.80 CHF +0.15
Yakult Honsha Co Ltd ¥7,430 JPY -100.00
View Industry Companies
 

Industry Analysis

BIOGB

Industry Average

Valuation BIOGB Industry Range
Price/Earnings 24.8x
Price/Sales 7.6x
Price/Book 10.6x
Price/Cash Flow 23.7x
TEV/Sales 6.8x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BIOGAIA AB-B SHS, please visit www.biogaia.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.